Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site managed by watchful waiting: A retrospective cohort study - 19/03/25
, Hayden Christensen, BA b, Hannah J. Porter, MD, MBA, MS a, Jenna Eaton, BS b, Jason Ludlow, BA b, Todd Holmes, MD a, Melanie R. Bui, MD, PhD aAbstract |
Background |
Treatment of cutaneous squamous cell carcinoma (cSCC) largely involves surgical excision. Few studies have examined oncologic outcomes of tumors managed by watchful waiting (WW) when the lesion appears resolved after the biopsy site has healed.
Objective |
To describe oncologic outcomes for patients diagnosed with cSCC that was determined clinically resolved at follow-up and subsequently managed by WW.
Methods |
This retrospective cohort included pathology proven cases of cSCC occurring from January 1st, 2013 to April 31st, 2023. Each required documented clinical resolution more than 4 weeks after biopsy, management by WW, and at least 12 months of follow-up.
Results |
Of 148 tumors managed by WW, there were 2 cases of local recurrence, and no cases of nodal metastasis, distant metastasis, or disease specific death. Log-rank test found significant risk of recurrence in immunocompromised participants (Hazard ratio = 12.87, P = .0193) and those with rheumatologic disease (Hazard ratio = 16.18, P = .0075).
Limitations |
Retrospective, single-center design.
Conclusion |
The recurrence rate in this cohort compares favorably to reported recurrence rates for surgically managed cSCC. In select cases, WW may be a reasonable management option for low-risk lesions that appear clinically resolved after healing of the biopsy site.
Le texte complet de cet article est disponible en PDF.Key words : clinical research, general dermatology, oncology, squamous cell carcinoma, watchful waiting
Abbreviations used : AJCC-8, BWH, cSCC, DSD, LR, MMS, NM, NMSC, SCCis, WW
Plan
| Dr Boudreaux and Author Christensen are co-first authors. |
|
| Funding sources: Supported in part by the University of Vermont Cancer Center. |
|
| Patient consent: Not applicable (no potentially identifying patient information included in manuscript). |
|
| IRB approval status: Reviewed and approved by The University of Vermont Institutional Review Board; approval STUDY 18-0402. |
Vol 92 - N° 4
P. 801-806 - avril 2025 Retour au numéro
Article précédent
- JAAD Game Changers: Consumption of dairy in teenagers with and without acne
- Eden Lake
- The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
- Joshua Burshtein, April Armstrong, May Chow, Lauren DeBusk, Alice B. Gottlieb, Linda Stein Gold, Neil J. Korman, Peter Lio, Joseph Merola, David Rosmarin, Angela Rosenberg, Abby Van Voorhees, Mark Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?